Drugs / Oprelvekin
Oprelvekin
also known as
IL-11 · Interleukin 11 · Neumega · rhIL-11 · Neumega (Oprelvekin, Interleukin 11, IL-11) · Recombinant Interleukin-11
Trials 5 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT00012298 | Apr 2001 → Apr 2010 | MALT lymphoma, Waldenstrom macroglobulinemia, chronic lymphocytic leukemia/small lymphocytic lymphoma, nodal marginal zone B-cell lymphoma +1 | National Cancer Institute (NCI) | Terminated | No outcome recorded |
| Phase 24 trials | ||||||
| Phase 2 | NCT00994929 | Jan 2010 → Apr 2012 | hemophilia A, von Willebrand disease (hereditary or acquired) | University of Pittsburgh | Completed | No outcome recorded |
| Phase 2 | NCT00886743 | Sep 2009 → Dec 2015 | thrombocytopenia | Pfizer | Terminated | No outcome recorded |
| Phase 2 | NCT00524225 | Feb 2008 → Jun 2012 | von Willebrand disease 1 | Margaret Ragni | Terminated | No outcome recorded |
| Phase 2 | NCT00524342 | Jan 2008 → Dec 2010 | von Willebrand disease 1 | Margaret Ragni | Completed | No outcome recorded |
Evidence & citations 9 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | oprelvekin | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00886743 ↗ |
| Known as | IL-11 | “Neumega (Oprelvekin, Interleukin 11, IL-11) 25 mcg/kg subcutaneously, given for 4 days preoperatively, and on day 5 preoperatively, and for up to 2 days postoperatively” NCT00524225 ↗1“Oprelvekin, Interleukin 11, IL-11” NCT00524342 ↗ |
| Known as | Interleukin 11 | “Neumega (Oprelvekin, Interleukin 11, IL-11) 25 mcg/kg subcutaneously, given for 4 days preoperatively, and on day 5 preoperatively, and for up to 2 days postoperatively” NCT00524225 ↗1“Oprelvekin, Interleukin 11, IL-11” NCT00524342 ↗ |
| Known as | Neumega | “Neumega (Oprelvekin, Interleukin 11, IL-11) 25 mcg/kg subcutaneously, given for 4 days preoperatively, and on day 5 preoperatively, and for up to 2 days postoperatively” NCT00524225 ↗ |
| Known as | Neumega (Oprelvekin, Interleukin 11, IL-11) | “Neumega (Oprelvekin, Interleukin 11, IL-11)” NCT00524342 ↗ |
| Known as | Recombinant Interleukin-11 | “Phase II Clinical Efficacy Trial of Recombinant Interleukin-11 (rhIL-11, Neumega) in Subjects With Type 1 Von Willebrand Disease Undergoing Surgery” NCT00524225 ↗ |
| Known as | rhIL-11 | “We, therefore, conducted a single-center Phase II clinical trial to determine safety and biologic efficacy of recombinant interleukin-11 (rhIL-11, Neumega®) in patients with...” PMID 23238591 ↗ Dec 20121“Phase II Clinical Efficacy Trial of Recombinant Interleukin-11 (rhIL-11, Neumega) in Subjects With Type 1 Von Willebrand Disease Undergoing Surgery” NCT00524225 ↗ |
| Modality | Protein / enzyme biologic | “Recombinant Interleukin-11” NCT00524225 ↗ |
| Route | Subcutaneous | “by subcutaneous injection” NCT00524225 ↗ |